# BridgeBio Oncology Therapeutics, Inc. (BBOT)

> Source: Nexqual · https://nexqual.com/BBOT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, BridgeBio Oncology Therapeutics, Inc. (BBOT), nexqual.com/BBOT" · informational, not investment advice.

**Price:** USD 2.95 (+1.55% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.91 · day 2.86–3.1 · 52w 2.86–14.87 · market cap $237M · NGM

## Key facts
- Analysts: Buy (mean 1.67 on a 1–5 scale) (12 analysts), mean target USD 24.55 (range 15–50).
- Total return with dividends: 1Y -74.1% vs S&P 500 +18.1%; 5Y -71.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.66, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 12 analysts; mean target USD 24.55 (low 15, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | JP Morgan | Target lowered | Overweight | $25 → $23 |
| 2026-09-10 | Leerink Partners | Target lowered | Outperform | $39 → $27 |
| 2026-09-09 | Canaccord Genuity | Target lowered | Buy | $23 → $20 |
| 2026-09-09 | Raymond James | Target lowered | Outperform | $24 → $22 |
| 2026-09-09 | Stifel | Target lowered | Buy | $23 → $15 |
| 2026-09-09 | Wedbush | Reiterated | Outperform | $25 |
| 2026-08-14 | JP Morgan | Target lowered | Overweight | $27 → $25 |
| 2026-07-08 | JP Morgan | Initiated | Overweight | $27 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2024-02-05) |
|---|---|---|
| Total return | -74.1% | -71.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -74.2% | -36.9% |
| Volatility (annualized) | 71.1% | 52.1% |
| Max drawdown | -78.8% (Nov 2025→Oct 2026) | -78.5% (Dec 2025→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/BBOT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt